NGM Biopharmaceuticals (NYSE:NGM) Major Shareholder Group L. P. Column Buys 53,172 Shares

Share on StockTwits

NGM Biopharmaceuticals (NYSE:NGM) major shareholder Group L. P. Column acquired 53,172 shares of NGM Biopharmaceuticals stock in a transaction on Friday, October 11th. The stock was acquired at an average price of $10.38 per share, with a total value of $551,925.36. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of NYSE:NGM opened at $10.27 on Tuesday. NGM Biopharmaceuticals has a 1 year low of $8.81 and a 1 year high of $19.27. The company has a fifty day simple moving average of $14.94.

NGM Biopharmaceuticals (NYSE:NGM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.71. The firm had revenue of $25.34 million for the quarter, compared to the consensus estimate of $19.00 million.

A number of research analysts have issued reports on the company. Stifel Nicolaus restated a “buy” rating and issued a $26.00 price objective on shares of NGM Biopharmaceuticals in a research note on Wednesday, August 14th. Zacks Investment Research upgraded NGM Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating, NGM Biopharmaceuticals presently has an average rating of “Buy” and a consensus target price of $24.20.

Several hedge funds have recently bought and sold shares of the company. Royal Bank of Canada bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $17,691,000. Svennilson Peter bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $229,762,000. Victory Capital Management Inc. bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $1,870,000. Citadel Advisors LLC bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $289,000. Finally, Pentwater Capital Management LP bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $309,000.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

Featured Story: Why Invest in Dividend Achievers?

Insider Buying and Selling by Quarter for NGM Biopharmaceuticals (NYSE:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.